Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice

[1]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[2]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[3]  Y. Mitsumoto,et al.  1-Methyl-4-phenylpyridinium (MPP+) Decreases Mitochondrial Oxidation-Reduction (REDOX) Activity and Membrane Potential (Δψm) in Rat Striatum , 2003, Experimental Neurology.

[4]  S. Speciale,et al.  MPTP: insights into parkinsonian neurodegeneration. , 2002, Neurotoxicology and teratology.

[5]  Y. Mitsumoto,et al.  Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice , 2002, Neuroscience Research.

[6]  Joseph P Huston,et al.  Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.

[7]  R. Schwarting,et al.  MPTP Susceptibility in the Mouse: Behavioral, Neurochemical, and Histological Analysis of Gender and Strain Differences , 2000, Behavior genetics.

[8]  M. Mattson,et al.  Participation of prostate apoptosis response‐4 in degeneration of dopaminergic neurons in models of Parkinson's disease , 1999, Annals of neurology.

[9]  M. Mattson,et al.  Dietary restriction and 2‐deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease , 1999, Journal of neuroscience research.

[10]  J. Martín,et al.  Effect of the Dopaminergic Neurotoxin MPTP on Cocaine-Induced Locomotor Sensitization , 1999, Pharmacology Biochemistry and Behavior.

[11]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[12]  E. López-Martín,et al.  The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.

[13]  A. Ho,et al.  Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease , 1998, The Journal of Neuroscience.

[14]  Y. Mitsumoto,et al.  Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.

[15]  Wiklund Ra,et al.  First of two parts , 1997 .

[16]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Kreutz,et al.  Amphetamine Induces Hypermotility in MPTP-Lesioned Mice , 1997, Pharmacology Biochemistry and Behavior.

[18]  L. Chia,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice , 1996, Neuroscience Letters.

[19]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Mitsumoto,et al.  The Insulin-dependent Biosynthesis of GLUT1 and GLUT3 Glucose Transporters in L6 Muscle Cells Is Mediated by Distinct Pathways , 1995, The Journal of Biological Chemistry.

[21]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[22]  H. L. Wiener,et al.  Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice , 1995, Neurochemical Research.

[23]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[24]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[25]  Yves Agid,et al.  Parkinson's disease: pathophysiology , 1991, The Lancet.

[26]  T. Kondo,et al.  Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPA , 1991, Neuroscience Letters.

[27]  A. Meneses,et al.  Effects of MPTP on locomotor activity in mice. , 1990, Neurotoxicology and teratology.

[28]  Y. Goshima,et al.  Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism , 1990, Brain Research.

[29]  R. Roth,et al.  Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 1989, Brain Research.

[30]  H. L. Wiener,et al.  Dopamine D1 receptor and dopamine D2 receptor binding activity chances during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice , 1989, Neuropharmacology.

[31]  J. Bruno,et al.  Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice , 1988, Neuroscience Letters.

[32]  A. Lajtha,et al.  Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease , 1987, Pharmacology Biochemistry and Behavior.

[33]  L. Olson,et al.  Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice , 1987, Brain Research.

[34]  W. Nicklas,et al.  IV. MPTP, MPP+ and mitochondrial function , 1987 .

[35]  G. Donnan,et al.  Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice , 1987, Brain Research.

[36]  Y. Mizuno,et al.  Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice , 1987, Journal of the Neurological Sciences.

[37]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[39]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[40]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[41]  P. Riederer,et al.  Time course of nigrostriatal degeneration in parkinson's disease , 1976, Journal of Neural Transmission.

[42]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[43]  T. Archer,et al.  MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN) , 2005, Journal of Neural Transmission.

[44]  P. Riederer,et al.  Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man , 2005, Journal of Neural Transmission.

[45]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[46]  M. Vila,et al.  The parkinsonian toxin MPTP: action and mechanism. , 2000, Restorative neurology and neuroscience.